

EA1131 Primary Analysis Dose Modification Data Description

This data dictionary is for NCT02445391-D2 dataset.

The data in the spreadsheet are the dose modification data for the primary manuscript on EA1131 results, published in

Mayer IA; Zhao F; Arteaga CL; Symmans WF; Park, Ben H; Burnette, Brian L; Tevaarwerk, Amye J; Garcia, Sofia F; Smith, Karen L; Makower, Della F; Block, Margaret; Morley, Kimberly A; Jani, Chirag R; Mescher, Craig; Dewani, Shabana J; Tawfik, Bernard; Flaum, Lisa E; Mayer, Erica L; Sikov, William M; Rodler, Eve T; Wagner, Lynne I; DeMichele, Angela M; Sparano JA; Wolff AC; Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. *J Clin Oncol.* 2021 Aug 10;39(23):2539-2551.

The data reflect the study database as of April 7, 2021.

Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Data File Description

Field	Variable Name	Description	Coding	Note
1	uid	Patient identifier		De-identified patient ID, not ECOG case ID
2	tx_mod_type	Treatment modification type	String variable	
3	tx_mod_reas	Treatment modification reason	1=adverse events or side effects 2=patient refusal or noncompliance 3=scheduling 88=other	
4	agnt_choice	Platinum agent	String variable	

Note: one patient can have dose modification in more than one cycle, so there could be more than one record for a single patient.